Evidence map›Paper›PMID 41368112›Full record

ArticleWorld journal of hepatology2025

Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma.

Li-Jun Wang, Yong Cui, Long-Fei Huang, Jing-Qing Zhang, Ting-Ting Zhao, Hong-Wei Wang, Ming Liu, Ke-Min Jin, Kun Wang, Bao-Cai Xing

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li-Jun WangDepartment of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Yong CuiDepartment of Radiology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Long-Fei HuangResearch Institute, GloriousMed Clinical Laboratory Co., Ltd., Shanghai 201318, China.
Jing-Qing ZhangResearch Institute, GloriousMed Clinical Laboratory Co., Ltd., Shanghai 201318, China.
Ting-Ting ZhaoResearch Institute, GloriousMed Clinical Laboratory Co., Ltd., Shanghai 201318, China.
Hong-Wei WangDepartment of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Ming LiuDepartment of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Ke-Min JinDepartment of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Kun WangDepartment of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Bao-Cai XingDepartment of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, Beijing 100142, China. xingbaocai88@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of immune checkpoint inhibitors and antiangiogenic drugs has shown promising efficacy in advanced hepatocellular carcinoma (HCC). However, tumor regression and progression-free survival (PFS) vary considerably among patients receiving this therapy.

aimTo identify predictive biomarkers in HCC patients treated with sintilimab (programmed cell death protein-1 inhibitor) plus lenvatinib (tyrosine kinase inhibitor).

methodsIn this single-center study in China, patients with unresectable HCC received sintilimab every 21 days and daily oral lenvatinib. Treatment response was assessed by modified response evaluation criteria in solid tumors. Tumor biopsies underwent RNA sequencing, immune microenvironment profiling, and whole-exome sequencing. Differentially expressed genes (DEGs) and immune cell subsets between response groups were identified, followed by survival analyses. All potential predictors of PFS, together with clinical variables, were included in Cox regression to identify independent prognostic factors.

resultsBetween August 2019 and November 2021, 33 patients with hepatitis-B-virus-related HCC were enrolled; by January 2024, 13 had undergone potentially curative surgery or ablation. RNA sequencing identified 94 DEGs between responders (

conclusionSintilimab plus lenvatinib showed heterogeneous efficacy in HCC. High

Indexed as

Hepatocellular carcinomaLenvatinibMolecular biomarkersRNA sequencingSintilimabWhole-exome sequencing

Identifiers

PMID41368112
PMCPMC12683347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.